AzTrials
AzTrials

Iron AbsorptionNCT03894358

Iron Absorption From a Wheat-based Instant Cereal:Gut and Stable Isotope Studies in Kenyan Infants

A study testing FeFum and 7.5 g prebiotic mixture, FeFum and 3 g prebiotic mixture and Fefum and no prebiotic mixture in people with Iron Absorption and Gut Microbiota, run by Swiss Federal Institute of Technology at 1 site in Kenya.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The aim of this study is to measure the effect of a prebiotic (high dose/low dose) mixture at different doses within a wheat-based instant cereal, on fractional iron absorption (FIA), gut microbiota and inflammation after three weeks. Read more about this study

Who is it for?
Ages 6 to 11 monthsHealthy volunteers can take part
Conditions the study is for
Iron Absorption, Gut Microbiota
What is being tested?
FeFum and 7.5 g prebiotic mixture, FeFum and 3 g prebiotic mixture and Fefum and no prebiotic mixture
Could I receive a placebo?
No, everyone receives an active treatment
How many people
195 participants
Where
1 siteKenya
Study dates
23 Jul 2019to 4 Jan 2020
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 to 11 months
  • All sexes
  • Healthy volunteers accepted
  • Child

Who may be able to join

  • 6 to 11 months at baseline
  • Anticipated residence in study area for the study duration
  • In good health as assessed by professional staff at Msambweni County Referral hospital
  • Caregiver is willing to participate and able to comply with study procedures
  • Informed consent form has been read and signed by the caregiver (or has been read out to the caregiver)

Who cannot join

  • Hemoglobin concentration less than 70 g/L
  • Severe underweight (Z-score weight-for-age <-3)
  • Severe wasting (Z-score weight-for-height <-3
  • Chronic or acute illness or other conditions that in the opinion of the Principal Investigator (PI) or study pediatrician would jeopardize the safety or rights of a participant in the trial or would render the participant unable to comply with the protocol
  • Participant taking part in other studies requiring the drawing of blood
  • Regular intake (>2 days) of iron-containing mineral and vitamin supplements or fortified foods within the last 2 months
  • Antibiotic treatment in the past 4 weeks prior to study enrollment

Trial locations and contacts

1 site in 1 country.

Kenya1 site
  • Msambweni County Referral Hospital

    Msambweni, Kwale County

Other trials in Kenya

About this study

Official title: Iron Absorption From a Wheat-based Instant Cereal Containing Ferrous Fumarate and Ascorbic Acid With and Without Prebiotics: Gut Microbiome and Stable Isotope Studies in Kenyan Infants

The aim of this study is to measure the effect of a prebiotic (high dose/low dose) mixture at different doses within a wheat-based instant cereal, on fractional iron absorption (FIA), gut microbiota and inflammation after three weeks. FIA will be compared with and without three weeks of pre-feeding with two different doses of the prebiotic mixture.

Read the detailed description

Iron deficiency anemia (IDA) is prevalent in infants and preschool children in sub-Saharan Africa. Several studies have been conducted to mitigate IDA. Some of these studies had adverse effects on the gut microbiome and diarrhea due to the high iron dose administered in areas of high burden of malaria and other common childhood infections. As a potentially safer solution, we investigated the effect of lowering the iron dose in the iron supplements and including 7.5 g galacto-oligosaccharides (GOS). Findings from these studies demonstrated that in infants, consumption of iron and GOS improved iron status, improved the gut microbiota and reduced risk of illness. We recently demonstrated that habitual consumption of GOS for three weeks resulted in improved iron absorption that correlated with a decrease in colonic pH. It is not known whether other prebiotics or a combination will also result in increased iron absorption and what the effect of using half the dose of prebiotics would be. The composition of Human Milk Oligosaccharides (HMOs) in breast milk might be an important determinant of the gut microbiome composition and health of the breastfed infant by determining the composition of Bifidobacteria species that are the main commensal 'barrier' bacteria in the infant's gut microbiome. However, little is known about the specific HMOs composition of breast milk in African populations and the potential impact on the gut microbiota composition of the breastfed infants. We therefore aim to measure the effect of a prebiotic (high dose/low dose) mixture at different doses within a wheat-based instant cereal, on fractional iron absorption (FIA) from a wheat-based instant cereal containing no prebiotic. We will compare the FIA with and without three weeks of pre-feeding with two different doses of prebiotic mixture. In addition, we will investigate the effect of two different doses of this prebiotic (high dose/low dose) mixture on gut microbiota and inflammation after three weeks.

In south coast Kenya, we will enroll 195 infants and randomize them into three intervention groups. Daily for 3 weeks, infants will consume a newly formulated wheat-based instant cereal (3.6 mg iron with Ascorbic acid (AA)) at home. Group 1 will receive the cereal with 7.5 g prebiotic mixture; group 2 will receive the cereal with 3 g prebiotic mixture and group 3 will receive the cereal with no prebiotics. In a subset of 70 infants, we will administer four labelled test meals. Two test meals will be fed 2 weeks before beginning the intervention study to investigate the acute effect of prebiotics on FIA and the other two will be fed at the end of the 3 weeks intervention study to investigate the effect of chronic consumption of prebiotics on FIA. Breast milk samples from the mothers will be collected and analyzed for the composition of human milk oligosaccharides (HMOs). We hypothesize that: 1) Infants receiving the new wheat-based instant cereal containing prebiotic (high dose/low dose) mixture will have a higher iron absorption, and 2) higher fecal Bifidobacteria abundance than infants receiving the cereal without prebiotics; 3) in infants receiving the wheat-based instant cereal, the addition of 7.5 g of prebiotic (high dose/low dose) mixture will result in higher FIA, and 4) in greater ratio of Bifidobacteria to Enterobacteriaceae, lowest fecal calprotectin, intestinal fatty acid-binding protein (I-FABP) and lowest abundances of enteropathogens than the addition of 3 g of prebiotics; 5) the addition of 7.5 g of prebiotic (high dose/low dose) mixture will result in greater FIA when administered acutely or chronically and these two effects will be additive; 6) the wheat-based instant cereal will improve iron status, including hemoglobin (Hb), plasma ferritin (PF) and soluble transferrin receptor (sTfR), and inflammation status, including C-reactive protein (CRP), alpha-1-acid glycoprotein (AGP), fecal calprotectin and I-FABP; 7) the wheat-based instant cereal will decrease fecal pH, thereby providing a less favorable growth environment for enteric pathogens; 8) Maternal secretor status will affect the infant gut microbiota, with infants of secretor mothers having higher abundances of Bifidobacterium and Bacteroides but lower abundances of enteropathogens; and 9) Effects of co-provision of prebiotic mixture on the infant gut microbiota and on iron absorption, will be stronger among infants of non-secretor mothers.

This study will generate crucial data for optimizing iron and prebiotic-composition of wheat-based instant cereal designed for complementary feeding during infancy. This cereal could potentially be part of continued research on interventions to reduce the burden of IDA using safer formulations not adversely affecting the infant's gut microbiome.

Being tested
FeFum and 7.5 g prebiotic mixture, FeFum and 3 g prebiotic mixture, Fefum and no prebiotic mixture

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • FeFum and 7.5 g prebiotic mixtureDietary supplement

    The 3 weeks intervention will consist of 24 g of wheat-based instant cereal and 90 ml of water per portion and will contain 3.6 mg FeFum and AA (molar ratio Fe:AA between 2.5 and 3) plus 7.5 g prebiotics mixture

    The absorption study test meals will consist of 24 g wheat-based instant cereal and 90 ml of water per portion and additionally:

    Test meal 1 will be composed of: 3.6 mg of Fe as 57FeFum and 0 g prebiotic mixture added extrinsically.

    Test meal 2 will be composed of: 3.6 mg of Fe as 1.5 mg iron as 58FeFum, 2.09 mg iron as 56FeFum and 7.5 g prebiotic mixture added extrinsically.

  • FeFum and 3 g prebiotic mixtureDietary supplement

    Standard wheat-based instant cereal containing 3.6 mg FeFum and AA (molar ratio Fe:AA between 2.5 and 3) plus 3 g prebiotics mixture per portion

  • Fefum and no prebiotic mixtureDietary supplement

    Standard wheat-based instant cereal containing 3.6 mg FeFum and AA (molar ratio Fe:AA between 2.5 and 3) per portion.

Study groups in NCT03894358
Study groupRoleWhat they receive
FeFum and 7.5 g prebiotic mixtureActive comparatorIntervention will be 3.6 mg Fe as Ferrous Fumarate and 7.5 g of prebiotic (high dose/low dose) mixture
Receives: Dietary Supplement: FeFum and 7.5 g prebiotic mixture
FeFum and 3 g prebiotic mixtureActive comparatorIntervention will be 3.6 mg Fe as Ferrous Fumarate and 3 g of prebiotic (high dose/low dose) mixture
Receives: Dietary Supplement: FeFum and 3 g prebiotic mixture
FeFum and no prebiotic mixtureActive comparatorIntervention will be 3.6 mg Fe as Ferrous Fumarate
Receives: Dietary Supplement: Fefum and no prebiotic mixture

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Fractional iron absorption (%)

    Fractional iron absorption (erythrocyte incorporation of stable iron isotopes after 14 days of meal) from the wheat-based instant cereal containing FeFum and AA, with and without a prebiotic mixture after single dosing

    Measured: Day 18

  2. Fractional iron absorption (%)

    Fractional iron absorption (erythrocyte incorporation of stable iron isotopes after 14 days of meal) from the wheat-based instant cereal containing FeFum and AA, with and without a prebiotic mixture after long-term dosing

    Measured: Day 57

Secondary outcomes (12)
  1. Change in fecal Bifidobacteria abundance

    Dose-dependent prebiotic mediated-effect (7.5 g vs. 3 g vs. 0 g prebiotic) on fecal Bifidobacteria abundance before and after 3-week intervention

    Measured: Day 18 and day 39

  2. Plasma ferritin

    Iron status measured at each blood draw

    Measured: Baseline, Day 18, Day 39, Day 57

  3. Soluble transferrin receptor

    Iron status measured at each blood draw

    Measured: Baseline, Day 18, Day 39, Day 57

  4. C-reactive protein

    Inflammation status measured at each blood draw

    Measured: Baseline, Day 18, Day 39, Day 57

  5. Alpha-1-acid glycoprotein

    Inflammation status measured at each blood draw

    Measured: Baseline, Day 18, Day 39, Day 57

  6. Change in fecal calprotectin

    Dose-dependent prebiotic mediated-effect (7.5 g vs. 3 g vs. 0 g prebiotic) on fecal calprotectin (inflammation marker) before and after 3-week intervention

    Measured: Day 18 and Day 39

  7. Change in intestinal integrity

    An indicator of gut inflammation; assessed by measuring Intestinal fatty acid binding protein (I-FABP) in fecal samples; Dose-dependent prebiotic mediated-effect (7.5 g vs. 3 g vs. 0 g prebiotic) before and after 3-week intervention

    Measured: Day 18 and day 39

  8. Change in gut microbiome composition

    Change in composition of the gut microbiome including pathogens; Dose-dependent prebiotic mediated-effect (7.5 g vs. 3 g vs. 0 g prebiotic) before and after 3-week intervention, assessed using qPCR, metagenomics and 16s sequencing

    Measured: Day 18 and day 39

  9. Change in fecal pH

    Dose-dependent prebiotic mediated-effect (7.5 g vs. 3 g vs. 0 g prebiotic) before and after 3-week intervention

    Measured: Day 18 and Day 39

  10. Short chain fatty acids concentrations

    Dose-dependent prebiotic mediated-effect (7.5 g vs. 3 g vs. 0 g prebiotic) before and after 3-week intervention

    Measured: Day 18 and day 39

  11. Change in viral load in nasopharynx

    Potential upper respiratory tract pathogens will be assessed in the nasopharyngeal swabs collected; Dose-dependent prebiotic mediated-effect (7.5 g vs. 3 g vs. 0 g prebiotic) before and after 3-week intervention

    Measured: Day 18 and day 39

  12. Maternal secretor status and HMO concentrations

    HMO concentrations in the breast milk of the mothers of the participating infants will be measured on day 39 and the maternal secretor status will be determined.

    Effect of maternal secretor status on the infant gut microbiota and response to iron fortificants with or without co-provision of prebiotics will be investigated

    Measured: Day 39

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Mar 2019
  2. Study start23 Jul 2019
  3. Primary completion4 Jan 2020
  4. Study completion4 Jan 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
195 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03894358
Sponsor's protocol ID
INSPIRE
Status last verified
May 2020
First submitted
7 Mar 2019
Last updated
12 May 2020
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Mikulic N, Uyoga MA, Stoffel NU, Derrien M, Nyilima S, Kostopoulos I, Roeselers G, Chenoll E, Mwasi E, Pironaci G, Karanja S, Bourdet-Sicard R, Zimmermann MB. Prebiotics increase iron absorption and reduce the adverse effects of iron on the gut microbiome and inflammation: a randomized controlled trial using iron stable isotopes in Kenyan infants. Am J Clin Nutr. 2024 Feb;119(2):456-469. doi: 10.1016/j.ajcnut.2023.11.018. Epub 2023 Nov 30.

    PubMed 38042412
  • Derrien M, Mikulic N, Uyoga MA, Chenoll E, Climent E, Howard-Varona A, Nyilima S, Stoffel NU, Karanja S, Kottler R, Stahl B, Zimmermann MB, Bourdet-Sicard R. Gut microbiome function and composition in infants from rural Kenya and association with human milk oligosaccharides. Gut Microbes. 2023 Jan-Dec;15(1):2178793. doi: 10.1080/19490976.2023.2178793.

    PubMed 36794816

Questions about this trial

What is this clinical trial studying?

A study testing FeFum and 7.5 g prebiotic mixture, FeFum and 3 g prebiotic mixture and Fefum and no prebiotic mixture in people with Iron Absorption and Gut Microbiota, run by Swiss Federal Institute of Technology at 1 site in Kenya.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 12 May 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Kenya. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Fractional iron absorption (%) (time frame: Day 18). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03894358, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 May 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in